Chronic lymphocytic leukemia therapy: new targeted therapies on the way.

ABSTRACT:

Introduction

The critical role of the tissue microenvironment and B-cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL) pathogenesis, and the clinical success of targeted agents that disrupt BCR signaling are currently changing the CLL landscape. Three new drugs were recently approved for CLL therapy, and other agents are in late development.

Areas covered

In this review, we summarize data on promising new targeted drugs for CLL. The heterogeneous mechanisms of actions of these molecules are described, such as the inhibition of BCR signaling, direct targeting of CD20 molecules on the CLL cell surface, and BCL-2 inhibition. We present preclinical and clinical data from phase I to III studies in order to describe efficacy and side effect profile of these new dr

SUBMITTER: Vitale C 

PROVIDER: S-EPMC4955400 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature